However, strategists could be forgiven for questioning the bank’s commitment to prime services, which sucks a lot of capital and only provides low returns. They could also be forgiven for questioning the bank’s commitment to IBD (and to equity and debt capital markets in particular) given IBD business is using capital but not generating great returns. Global macro products professionals also look like they’re on shaky ground, despite the improving market conditions. Part of the problem, as I see it,…